Intraocular pressure

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Retrieved on: 
Saturday, April 6, 2024
IOP, Glaucoma, Conditional sentence, Ocular hypertension, Endothelium, Arm, Medicine, Safety, Risk, ASCRS, Patient, Protocol, MD, Genetically modified bacteria, Science, Intraocular pressure, Travoprost, FDA

BEDFORD, Mass., April 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced positive Phase 2 data for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension (reported together as “glaucoma”, below) The data are being presented by Mark Gallardo, MD during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

Key Points: 
  • “Ocular is very pleased to report positive six-month topline results for PAXTRAVA in the Phase 2 glaucoma study.
  • We designed the Phase 2 clinical trial to evaluate PAXTRAVA over several time points that we believe are clinically meaningful, through six months.
  • Most ocular AEs within 3 days were deemed related to the injection procedure by the investigators.
  • I am enthusiastic about PAXTRAVA because of the positive, durable IOP reductions, accompanied by a good overall safety profile,” said Mark Gallardo, MD.

SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Retrieved on: 
Tuesday, April 2, 2024
IOP, Bimatoprost, Glaucoma, Ocular hypertension, Pressure, IOL, ASCRS, Patient, Tissue, Cataract, Month, Spyglass, Visual acuity, Society, Safety, IOPS, Therapy, FDA, Intraocular pressure, Annual general meeting, Pharmaceutical industry

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5-8 in Boston.

Key Points: 
  • ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery.
  • The SpyGlass platform was well tolerated and there were no adverse events related to the product.
  • These data highlight the substantial potential of the SpyGlass Drug Delivery Platform to be a game changer for patients and all cataract surgeons.”
    “SpyGlass technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO, SpyGlass PharmaTM.
  • The compelling clinical data released this week suggest we are on track to bringing our innovative platform to patients.”
    The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues.

Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology

Retrieved on: 
Wednesday, March 20, 2024
IOP, Ocular hypertension, Professor, NCX, Patient, American Journal, American Journal of Ophthalmology, Glaucoma, Vision science, Intraocular pressure, Pharmaceutical industry

Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025

Key Points: 
  • Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025
    Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.
  • “The data from the Mont Blanc Phase 3 trial demonstrated the potential of NCX 470 and we look forward to seeing confirmation of this clinical profile in the upcoming results from the ongoing Denali Phase 3 trial, expected in H2 2025.
  • The Mont Blanc publication concludes that “The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with open-angle glaucoma or ocular hypertension at all 6 time points.
  • With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.”

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Retrieved on: 
Monday, March 18, 2024
Research, Adverum Biotechnologies, Vasculitis, Three Months, Macula, Chorioretinitis, Inflammation, Patient, Episcleritis, American Academy, Anti-VEGF, LUNA, Intraocular pressure, Investment, Clinical trial, Injection, Safety, Drug development, Paratriathlon, AMD, AAO, OPTIC, Retinitis, CST, Vascular occlusion, Annual general meeting, VEGF, Pharmaceutical industry

REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.

Key Points: 
  • The company also provided recent pipeline highlights and corporate updates.
  • 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
  • Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.

Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024

Retrieved on: 
Wednesday, March 13, 2024
Mont Blanc, IOP, OCT, Whistler, Glaucoma, Ocular hypertension, Fluticasone, Database, Intraocular pressure, NCX, COVID-19, Patient, NDA, BlackRock, Sale, Bausch & Lomb, Therapy, Retina, Allergic conjunctivitis, Safety, Patent, Telecanthus, FDA, Corporation, Food, Pharmaceutical industry

“Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.

Key Points: 
  • “Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.
  • We are reducing costs, including the size of the organization, and are exploring advancing NCX 1728, through collaborations.
  • In January 2024, Nicox expanded the territory of the exclusive licensing agreement with Harrow, Inc., to include Canada.
  • The Company is financed to at least November 2024, based on focusing exclusively on the development of NCX 470.

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Retrieved on: 
Wednesday, April 3, 2024
Medical Devices, Surgery, Health Technology, Health Insurance, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Optical, Retina, IOP, HCPCS, Glaucoma, Ocular hypertension, OAG, OHT, Patient, Corporation, APC, Eye, Surgeon, CPT, Travoprost, GKOS, OPPS, Idose, Medicare, CMS, Government, Intraocular pressure

The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.

Key Points: 
  • The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
  • It is expected to increase patient access in the U.S. and has been published here on the CMS website.
  • “The receipt of a product-specific J-code for iDose TR supports our market access initiatives to enable broad access and coverage for patients suffering from open-angle glaucoma or ocular hypertension,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.

Center For Sight Implants New FDA-Approved iDose®TR Device

Retrieved on: 
Tuesday, March 26, 2024
Surgery, Medical Devices, FDA, Hospitals, Biotechnology, Other Health, Health, General Health, Optical, Optic nerve, Ocular hypertension, Paratriathlon, Patient, Cataract, Eye, Multimedia, Intraocular pressure, Food, Medical device

The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.

Key Points: 
  • The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.
  • The device consistently distributes a travoprost formula to help reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
  • is a member of the US Eye Physician Advisory Board and is a Cataract and Glaucoma Surgeon at Center For Sight.
  • Speaking of the device, he shares, “We found the device and medication formula to work very well in our study patients.

Prevent Blindness Provides Free Resources as Part of April's Women's Eye Health and Safety Month to Educate Women on Necessary Steps to Help Save Sight

Retrieved on: 
Wednesday, March 27, 2024
Orbis, IOP, Pigment, Glaucoma, Le Bonheur Children's Hospital, Social media, Pressure, Visual impairment, Contact, Paratriathlon, Intraocular pressure, AAO, Policy, Orbis International, Hormone, Diabetes, Risk, Mental health, Delta Gamma, NIH, Eyelid, Prevalence, Eye, Associate, Safety, Cataract, Menopause, University, Pregnancy, Hospital, Melasma, Public health, Lactation, Puberty, American Academy, Lens, Telecanthus, Eye disease, Graves' ophthalmopathy, Bangladesh Technical Education Board, Dry eye syndrome, Pediatrics, Birth control

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month. According to Orbis International, globally there are 112 million more women than men living with vision loss, including blindness. Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.

Key Points: 
  • CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month.
  • Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.
  • Women have a higher prevalence of age-related macular degeneration, cataract, dry eye, glaucoma, refractive error and thyroid eye disease.
  • For more information on women's eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org.

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

Retrieved on: 
Friday, March 8, 2024
FACS, Regeneron Pharmaceuticals, Research, HD, Food, Floater, Cataract, Consultant, Aflibercept, Diabetic retinopathy, European, Intraocular pressure, Safety, DR, Society, Retinal, Bayer, Diabetes, Patient, Publication, Pharmaceutical industry

TARRYTOWN, N.Y., March 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for EYLEA® HD (aflibercept) Injection 8 mg. Specifically, the publications detailed data demonstrating that EYLEA HD extended dosing regimens were non-inferior to EYLEA® (aflibercept) Injection 2 mg for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

Key Points: 
  • Specifically, the publications detailed data demonstrating that EYLEA HD extended dosing regimens were non-inferior to EYLEA® (aflibercept) Injection 2 mg for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
  • “Less than a year after its approval, EYLEA HD has already made an impact in the treatment of wet age-related macular degeneration and diabetic macular edema.
  • EYLEA HD has provided disease control for my tough-to-treat cases of diabetic eye disease and allowed both my diabetic and wet age-related macular degeneration patients to enjoy less frequent dosing with a similar safety profile to EYLEA.”
    PULSAR and PHOTON are two double-masked, active-controlled pivotal trials evaluating EYLEA HD compared to EYLEA.
  • In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

Retrieved on: 
Thursday, March 7, 2024
ASPS, IOP, Research, Randomized controlled trial, OMNI, Growth, Ophthalmology, Telecanthus, Nature, Intraocular pressure, Safety, GAAP, Medicare, Patient, News, Webcast, Clinical trial, Uncertainty, Security (finance), LCD, Environment, Depreciation, Pharmaceutical industry

Reduced cash used to $6.4 million in the fourth quarter of 2023 compared to $10.0 million used in the third quarter of 2023, a decrease of 36%, and $14.8 million used in the fourth quarter of 2022, a decrease of 57%.

Key Points: 
  • Reduced cash used to $6.4 million in the fourth quarter of 2023 compared to $10.0 million used in the third quarter of 2023, a decrease of 36%, and $14.8 million used in the fourth quarter of 2022, a decrease of 57%.
  • Gross profit for the fourth quarter of 2023 was $16.0 million compared to $16.9 million in the same period in the prior year.
  • Gross margin for the fourth quarter of 2023 was 85%, compared to 82% in the same period in the prior year.
  • Sight Sciences' management team will host a conference call today, March 7, 2024, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.